Is Syndax Pharmaceuticals Inc (NASDAQ:SNDX)’s Fuel Running High? Reports Show Less Sellers

June 10, 2018 - By Henry Gaston

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Logo

The stock of Syndax Pharmaceuticals Inc (NASDAQ:SNDX) registered a decrease of 2.49% in short interest. SNDX’s total short interest was 977,400 shares in June as published by FINRA. Its down 2.49% from 1.00 million shares, reported previously. With 160,000 shares average volume, it will take short sellers 6 days to cover their SNDX’s short positions. The short interest to Syndax Pharmaceuticals Inc’s float is 5.83%.

The stock increased 3.44% or $0.27 during the last trading session, reaching $8.11. About 167,357 shares traded. Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) has declined 29.80% since June 10, 2017 and is downtrending. It has underperformed by 42.37% the S&P500.

Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The company has market cap of $200.36 million. The companyÂ’s lead product candidate is Entinostat, which is in Phase III clinical trial for the treatment of hormone receptor positive, human epidermal growth factor receptor 2 negative, and breast cancer; and Phase 2b clinical trial. It currently has negative earnings. It also develops SNDX-6352, an immunoglobulin G subclass 4 isotype that binds to the ligand binding domain of CSF-1R, blocking the binding and consequent activation by natural ligands interleukin-34 and colony stimulating factor-1, and disrupting tumor-associated macrophages activity.

More notable recent Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) news were published by: which released: “Syndax down 22% on mid-stage entinostat data” on May 17, 2018, also with their article: “Syndax and Nektar Therapeutics team up in study of doublet therapy for advanced melanoma” published on May 30, 2018, published: “Syndax: One Step Backward, Two Forward?” on May 23, 2018. More interesting news about Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) were released by: and their article: “Syndax Pharmaceuticals (SNDX) ENCORE 601 Update – Slideshow” published on May 18, 2018 as well as‘s news article titled: “Syndax Pharmaceuticals: Elucidating The Results Of The Phase 2 ENCORE 601 Trial” with publication date: May 28, 2018.

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: